UIA
CRL icon

Ulland Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Ulland Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$2K – 224
2024
Q1 		$2K Buy
+6
New +$1.43K ﹤0.01% 211

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ulland Investment Advisors's CRL Position: Q2 2024 in Review

Ulland Investment Advisors sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 6 shares — an estimated $2K sold.

Ulland Investment Advisors first reported a position in CRL in Q1 2024 and held it in 1 quarter. The position peaked at $2K in Q1 2024. 664 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Ulland Investment Advisors reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Ulland Investment Advisors sold 6 Charles River Laboratories shares in Q2 2024, an estimated $2K.
  • Ulland Investment Advisors first reported a position in Charles River Laboratories in Q1 2024 and held it in 1 quarter.
  • Ulland Investment Advisors's Charles River Laboratories position peaked at $2K in Q1 2024.
  • 664 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Ulland Investment Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.